Subscribe: B3C newswire I
http://www.b3cnewswire.com/index.php?option=com_bca-rss-syndicator&feed_id=2
Preview: B3C newswire I

B3C newswire



Latest biotech news from B3C newswire (short version)



Last Build Date: Thu, 22 Feb 2018 00:01:37 +0100

 



Serious About Serialisation: DCC Vital Selects rfxcel for EU FMD Compliance

Wed, 21 Feb 2018 09:30:00 +0100

San Ramon, CA, USA, February 21, 2018 / B3C newswire / -- rfxcel Corporation , a customer-focused serialisation and track and trace provider for the Life Sciences industry, announced today that DCC Vital, a manufacturer headquartered in Dublin, Ireland, has selected rfxcel to meet its European Falsified Medicines Directive (EU FMD) serialisation requirements.

As a European manufacturer of pharmaceuticals and medical devices, and a logistics provider in the UK, DCC Vital prides themselves in their ability to deliver solutions that will make a difference to patient care. Over the past 5 years, DCC Vital has more than doubled ...




Selvita Announces Successful Completion of $41 M Book Building

Fri, 16 Feb 2018 14:15:00 +0100


*** NOT FOR DISTRIBUTION IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN ***

Krakow, Poland, February 16, 2018 / B3C newswire / -- Selvita (WSE:SLV), one of the largest drug discovery companies in Europe, has received investment declarations implicating placement of all 2,200,000 shares offered in the H series public subscription. The issue price was set at the previously announced maximum limit of PLN 61.00 per share. The amount of gross proceeds raised in the offering, before estimated expenses of the offering, is approximately PLN 134.2 million ($40.57 million). The funds ...




Vetter Is a Winner of the Fraunhofer Clean Manufacturing Award CLEAN! 2018

Thu, 15 Feb 2018 15:30:00 +0100

Pharmaceutical service provider convinces jury with its innovative cleanroom technology V-CRT®

  • Vetter comes in 3rd at CLEAN! 2018
  • Fraunhofer IPA honors innovative groundbreaking developments in clean technology
  • The holistic and innovative manufacturing technology V-CRT® from Vetter convinces an expert jury with its aseptic safety

Karlsruhe, Germany, February 15, 2018 / B3C newswire / -- Vetter is one of the winners of the clean manufacturing award CLEAN! 2018. The pharmaceutical service provider was able to convince the independent expert jury of the Fraunhofer Institute for Manufacturing Engineering and Automation (IPA) with its innovative Vetter CleanRoom Technology V-CRT®. The prize was ...




Orchard Therapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference

Tue, 13 Feb 2018 14:45:00 +0100

London, UK, February 13, 2018 / B3C newswire / -- Orchard Therapeutics , a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, today announced that Mark Rothera, Orchard’s president and chief executive officer, will present at the RBC Capital Markets 2018 Global Healthcare Conference in New York City on Wednesday, February 21, 2018 at 10:30 a.m. ET.

 
About  Orchard Therapeutics
Orchard Therapeutics is a privately held clinical-stage biotechnology company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies. Orchard, based in the UK and US, has ...




New ISOLUTE® HYDRO DME+ Rapidly Removes Matrix Interferences from Urine

Tue, 13 Feb 2018 14:30:00 +0100

Uppsala, Sweden, February 13, 2018 / B3C newswire / -- Biotage (STO: BIOT), a leading global supplier of solutions and technology for analytical, medicinal and peptide chemistry, is pleased to announce the launch of ISOLUTE® HYDRO DME+ fixed well plates and columns, for the efficient removal of matrix components from urine, using a simple pass through workflow.

The novel (patent pending) dual mode extraction (DME) methodology has been developed by Biotage to provide more effective removal of matrix components such as salts, creatinine, urea, pigments and residual hydrolysis enzymes from urine using a combination of liquid partitioning ...




ProBioGen and TEVA Sign License Agreement on Human Artificial Lymph Node Technology

Wed, 07 Feb 2018 10:00:00 +0100

Research License Agreement on Unique Technology to Assess Drug Effects on the Immune System in Vitro

Berlin, Germany, February 07, 2018 / B3C newswire / -- ProBioGen , a leading specialist for contract development and manufacturing of complex glycoproteins today announced the signature of a non-exclusive license agreement on its proprietary human Artificial Lymph Node (HuALN) platform technology with TEVA. The unique human Artificial Lymph Node model was developed by ProBioGen as superior 3D-micro-organoid model for analyzing substance effects on the human immune system in vitro.

Under the terms of the agreement the technology platform will be transferred to ...




Selvita Appoints Steffen Heeger, M.D., PhD as Chief Medical Officer

Tue, 06 Feb 2018 09:00:00 +0100

Kraków, Poland, February 06, 2018 / B3C newswire / -- Selvita S.A. (WSE:SLV), a clinical stage drug discovery and development company focused on innovative medicines for oncology patients and drug discovery services, announced today the appointment of Steffen Heeger, M.D., PhD, to the role of Chief Medical Officer.

Dr. Heeger will join Selvita in February and will be responsible for all clinical, medical affairs and regulatory functions for Selvita oncology pipeline including SEL24 , the first-in-class dual PIM/FLT3 kinase inhibitor currently in Phase I/II studies in acute myeloid leukemia, SEL120 , the first-in-class selective CDK8 kinase ...




Orchard Therapeutics Appoints Dr. Harry Malech to Scientific Advisory Board

Mon, 05 Feb 2018 09:00:00 +0100

London, UK, February 05, 2018 / B3C newswire / -- Orchard Therapeutics , a clinical-stage biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, today announced the appointment of Harry Malech, M.D., to its scientific advisory board (SAB). Dr. Malech will be contributing his time and expertise ad honorem.

Dr. Malech is a globally recognized expert in primary immune deficiencies (PIDs) and gene therapy. Dr. Malech is currently deputy chief of the Laboratory of Clinical Immunology and Microbiology (LCIM) and chief of the Genetic Immunotherapy Section (GIS) at the National Institute of ...




Vetter Introduces South Korea’s Pharma and Biotech Community to Meet Company Management

Fri, 02 Feb 2018 15:00:00 +0100

Songdo, South Korea and Ravensburg, Germany, February 02, 2018 / B3C newswire / -- In an event at its new branch office attended by key customers and business associates, Vetter’s senior management representatives presented the company’s service portfolio along with its growth strategy for South Korea and the Asia Pacific (APAC) region. In addition, attendees were introduced to Mr. Michael Yi who will manage the office in his role as Business Development Manager for Vetter Pharma International GmbH, South Korea. Mr. Yi, who is based in Songdo, has pharmaceutical experience in responsible business development roles at several companies. He reports ...




ZZ Biotech Announces Preliminary Phase 2 Stroke Trial Results with 3K3A-APC

Mon, 29 Jan 2018 09:00:00 +0100

Houston, TX, USA, January 29, 2018 / B3C newswire / -- ZZ Biotech today announced that preliminary results of RHAPSODY, the company’s Phase 2 clinical trial in acute ischemic stroke patients, were presented at the 2018 International Stroke Conference in Los Angeles.

The placebo-controlled dose-escalation trial was designed to establish a maximally tolerated dose (MTD) of 3K3A-APC in patients with acute ischemic stroke treated with intravenous tPA, intra-arterial thrombectomy, or both. A secondary endpoint was to evaluate the effect of 3K3A-APC on cerebral hemorrhage in this patient population. Study participants, aged 18-90, were followed for 90 days.

The ...




Araclon Biotech Partners with TFS International for Their Alzheimer’s Phase II Trial

Thu, 25 Jan 2018 14:00:00 +0100

Lund, Sweden, January 25, 2018 / B3C newswire / -- After completing a successful phase I partnership with TFS International (TFS), Araclon Biotech a Grifols company, decided to continue the partnership with TFS advancing their Alzheimer’s disease (AD) vaccine ABvac40 into phase II.  The placebo-controlled phase II trial will be carried out at 21 clinical investigational sites across Europe over the next two years.

AD is a progressive disease associated with the accumulation, aggregation, and deposition of amyloid beta (Abeta) peptides in the brain. Abeta deposition may precede symptoms by many years. New therapies based on vaccines with ...




FuturaGene's Exclusive License for RNAi Technology in Eucalyptus Enhanced by Grant of Patent in Brazil

Wed, 17 Jan 2018 17:05:00 +0100

Canberra, Australia and Sao Paulo, Brazil, January 17, 2018 / B3C newswire / -- FuturaGene , a wholly owned subsidiary of Suzano Pulp and Paper, and Australia’s Commonwealth Scientific and Industrial Research Organisation (CSIRO), are pleased to announce that a patent has been issued in Brazil to CSIRO, which covers the downregulation of the expression of plant target genes or other target genes, including genes of insect pests and disease agents. In 2014, FuturaGene entered into an exclusive license agreement with CSIRO for the use of RNAi technology in eucalyptus in Brazil. Under the license, FuturaGene has ...




Orchard Therapeutics Appoints Frank Thomas as Chief Financial Officer and Chief Business Officer

Wed, 17 Jan 2018 09:00:00 +0100

London, UK, January 17, 2018 / B3C newswire / -- Orchard Therapeutics , a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, today announced the appointment of Frank Thomas to the newly created position of chief financial officer and chief business officer.

Thomas brings nearly 20 years of experience in the biopharmaceutical industry as an accomplished financial and business executive with an extensive set of capabilities to Orchard. Mr. Thomas has a background developing and executing capital markets strategies for private and public companies as well as experience in operations management, ...




Batavia Biosciences Teams Up with International Consortium to Support Polio Eradication

Tue, 16 Jan 2018 10:30:13 +0100

Leiden, the Netherlands, January 16, 2018 / B3C newswire / -- Today Batavia Biosciences announces its partnership with an international consortium coordinated by PATH aiming to develop and manufacture safer novel oral poliovirus vaccines (nOPV). The project, funded by the Bill & Melinda Gates Foundation, has the potential to bolster efforts to sustain a polio-free world after the disease has been eradicated.

With a 99% reduction in polio cases worldwide since 1988, the global eradication of polio is now in sight. In support of the polio eradication initiative, novel oral polio vaccine (nOPV) candidates are being developed that ...




BioNTech Announces Results from Two More Studies Demonstrating the Benefits of Breast Cancer Subtyping Using Mammatyper®

Mon, 15 Jan 2018 15:00:00 +0100

  • MammaTyper® is superior to local immunohistochemistry (IHC) for measuring local gene expression in order to predict Oncotype DX®-type results(1)
  • Use of MammaTyper® subtyping for prognosis of breast cancer suggests that endocrine therapy­ may be adequate for patients with a low risk of relapse(2)
  • This study demonstrated that MammaTyper® is a cost-effective method to identify low-risk patients.

Mainz, Germany, January 15, 2018 / B3C newswire / -- BioNTech Diagnostics GmbH is announcing new results from two studies on the MammaTyper® test which were presented at the Breast Cancer Symposium in San Antonio in December.(1,2) The results of these studies ...